| Pharmaceutical Information |
| Drug Name |
Idursulfase |
| Drug ID |
BADD_D01132 |
| Description |
Idursulfase is a purified form of human iduronate-2-sulfatase, a lysosomal enzyme. Idursulfase is produced by recombinant DNA technology in a human cell line. Idursulfase is an enzyme that hydrolyzes the 2-sulfate esters of terminal iduronate sulfate residues from the glycosaminoglycans dermatan sulfate and heparan sulfate in the lysosomes of various cell types. Idursulfase is a 525-amino acid glycoprotein with a molecular weight of approximately 76 kilodaltons. The enzyme contains eight asparagine-linked glycosylation sites occupied by complex oligosaccharide structures. The enzyme activity of idursulfase is dependent on the post-translational modification of a specific cysteine to formylglycine. |
| Indications and Usage |
For the treatment of Hunter syndrome in adults and children ages 5 and older. |
| Marketing Status |
Prescription |
| ATC Code |
A16AB09 |
| DrugBank ID |
DB01271
|
| KEGG ID |
D04499
|
| MeSH ID |
C517982
|
| PubChem ID |
Not Available
|
| TTD Drug ID |
D06CZJ
|
| NDC Product Code |
54092-700 |
| Synonyms |
idursulfase | Elaprase |
|
| Chemical Information |
| Molecular Formula |
Not Available |
| CAS Registry Number |
50936-59-9 |
| SMILES |
Not Available |
| Chemical Structure |
|
|
| ADR Related Proteins Induced by Drug |
| ADR Term |
Protein Name |
UniProt AC |
TTD Target ID |
PMID |
| Not Available | Not Available | Not Available | Not Available | Not Available |
|
| ADRs Induced by Drug |
|
|
